MediciNova, Inc.

NasdaqGM:MNOV Voorraadrapport

Marktkapitalisatie: US$104.5m

MediciNova Toekomstige groei

Future criteriumcontroles 0/6

MediciNova's winst zal naar verwachting dalen met 6.1% per jaar. De winst per aandeel zal naar verwachting dalen met 4.8% per jaar.

Belangrijke informatie

-6.1%

Groei van de winst

-4.8%

Groei van de winst per aandeel

Biotechs winstgroei28.3%
Inkomstengroein/a
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt30 Sep 2024

Recente toekomstige groei-updates

Recent updates

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Apr 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Nov 27
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Jul 11
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Winst- en omzetgroeiprognoses

NasdaqGM:MNOV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026N/A-12N/AN/A1
12/31/2025N/A-12N/AN/A1
12/31/2024N/A-11N/AN/A1
9/30/2024N/A-10-9-9N/A
6/30/20241-8-9-9N/A
3/31/20241-8-8-8N/A
12/31/20231-9-7-7N/A
9/30/20231-10-11-11N/A
6/30/2023N/A-12-12-12N/A
3/31/2023N/A-14-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-13-13-13N/A
6/30/20220-13-13-13N/A
3/31/20220-13-9-9N/A
12/31/20214-10-9-9N/A
9/30/20214-11-8-8N/A
6/30/20214-11-9-9N/A
3/31/20214-11-12-12N/A
12/31/2020N/A-14-11-11N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-12-9-9N/A
3/31/2020N/A-11-9-9N/A
12/31/2019N/A-13-9-9N/A
9/30/2019N/A-11-8-8N/A
6/30/2019N/A-16-8-8N/A
3/31/2019N/A-15-8-8N/A
12/31/2018N/A-15-9-9N/A
9/30/2018N/A-16-9-9N/A
6/30/2018N/A-13N/A-9N/A
3/31/2018N/A-13N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-7N/A
6/30/2017N/A-10N/A-7N/A
3/31/2017N/A-11N/A-7N/A
12/31/2016N/A-11N/A-7N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-7N/A
9/30/2015N/A-8N/A-7N/A
6/30/2015N/A-9N/A-7N/A
3/31/2015N/A-9N/A-7N/A
12/31/2014N/A-9N/A1N/A
9/30/20146-3N/A-2N/A
6/30/20146-3N/A-2N/A
3/31/20146-4N/A-3N/A
12/31/20136-4N/A-11N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MNOV de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MNOV de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MNOV de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van MNOV naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat MNOV volgend jaar geen omzet zal hebben.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MNOV naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven